PHGE

PHGE

USD

BiomX Inc. COmmon Stock

$0.440-0.020 (-4.348%)

Real-time Price

Healthcare
Biotechnology
Israel

Price Chart

Loading Chart...

Key Metrics

Market Metrics
Company Fundamentals
Trading Stats

Market Metrics

Open

$0.460

High

$0.463

Low

$0.435

Volume

0.13M

Company Fundamentals

Market Cap

11.5M

Industry

Biotechnology

Country

Israel

Trading Stats

Avg Volume

0.13M

Exchange

ASE

Currency

USD

52-Week Range

Low $0.43Current $0.440High $3.86

Related News

GlobeNewswire

BiomX CEO Jonathan Solomon to Present at Biomed Israel 2025 Conference

NESS ZIONA, Israel, May 19, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic

View more
BiomX CEO Jonathan Solomon to Present at Biomed Israel 2025 Conference
Analyst Upgrades

HC Wainwright & Co. Maintains Buy on BiomX, Lowers Price Target to $15

HC Wainwright & Co. analyst Joseph Pantginis maintains BiomX with a Buy and lowers the price target from $21 to $15.

View more
HC Wainwright & Co. Maintains Buy on BiomX, Lowers Price Target to $15
GlobeNewswire

BiomX Reports First Quarter 2025 Financial Results and Provides Business and Program Updates

In March 2025, BiomX announced positive topline results of the phase 2 trial evaluating BX211 for the treatment of diabetic foot osteomyelitis (DFO) BX004 Phase 2b study in Cystic Fibrosis (CF) on track to report

View more
BiomX Reports First Quarter 2025 Financial Results and Provides Business and Program Updates
GlobeNewswire

BiomX to Host First Quarter 2025 Financial Results Conference Call and Webcast on May 15, 2025

NESS ZIONA, Israel, May 08, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic

View more
BiomX to Host First Quarter 2025 Financial Results Conference Call and Webcast on May 15, 2025